Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific antibody from 3Sbio Inc. that recently won China clearance for a phase III study in lung cancer as a potential first-line monotherapy. Announced after U.S. market hours May 19, the exclusive agreement for SSGJ-707 spells up to $6.15 billion combined for Shenyang, China-based 3Sbio, along with separate tiered double-digit royalty payments on sales of SSGJ-707, if approved.
Scientists at Jubilant Biosys Ltd. and the University of Texas System have divulged fatty acid binding protein (FABP) inhibitors reported to be useful for the treatment of cancer.
ADC Therapeutics SA has described antibody-drug conjugates comprising antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi-2b) covalently linked to exatecan through a linker reported to be useful for the treatment of ovarian cancer and non-small-cell lung cancer (NSCLC).
The U.S. FDA granted Abbvie Inc. accelerated approval for antibody-drug conjugate (ADC) Teliso-V (telisotuzumab vedotin), newly branded Emrelis, making it the first treatment for previously treated advanced non-small-cell lung cancer with high c-Met protein overexpression.
TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung cancer using belrestotug, an anti-TIGIT monoclonal antibody, were disappointing so the companies are calling it a day.
Radiopharmaceuticals can offer a targeted approach for cancers that have limited therapeutical options. Abdera Therapeutics Inc. recently presented results of their novel 5T4-targeted radiopharmaceutical.
Epidermal growth factor receptor (EGFR), when overactive or overexpressed, may lead to tumor growth and spread, and is thus a robust target for therapy.
Researchers from Osaka University have developed a novel approach to target nicotinamide N-methyltransferase (NNMT), an enzyme implicated in cancer progression, using antisense oligonucleotides (ASOs).
Folate receptor α (FOLR1) is highly expressed in the surface of tumoral cells in several cancer types, while it shows limited expression in normal tissues. CSPC Pharmaceutical Group Ltd. has developed a next-generation antibody-drug conjugate (ADC) targeting FOLR1 – SYS-6041 – for the treatment of mid-to-low FOLR1-expressing tumors.
Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.
